Product Image
Invitrogen™

Novex™ 18% Tris-Glycine Mini Protein Gels, 1.0 mm, 10-well

Have Questions?
货号 EC6505BOX
价格(CNY)
2,962.00
10 gels (1 box)
价格(CNY)
2,962.00
10 gels (1 box)
Novex® 18% Tris-Glycine Mini Gels are polyacrylamide gels based on traditional Laemmli protein electrophoresis. Novex® Tris-Glycine gels provide reproducible separation of a wide range of proteins into well-resolved bands. Each box contains 10 gels. Features of these gels:

•   Individually packaged gels for optimal experiment design
•   Compatible with most protein standards
•   Usable for native and denaturing protein assays

Choose the right gel format for your experiments
Novex® Tris-Glycine gels come in a variety of fixed concentrations from 4% to 18%, as well as gradients with ranges of 4–12%, 4–20%, 8–16%, and 10–20%. You can also select between our mini (8 cm x 8 cm) and our midi (8 cm x 13 cm) sizes, as well as multiple well-formats from 1 well to 26 wells.

For best results, most Novex® Tris-Glycine gels should be stored at 4°C and used within 8 weeks of purchase. Novex® 16% and 18% Tris-Glycine gels should be used within 4 weeks of purchase.

Run your proteins in native or denatured form

Novex® Tris-Glycine gels do not contain SDS and can be used to run your proteins in native or in denatured form. For denatured proteins, we recommend using Novex® Tris-Glycine SDS Sample Buffer and Novex® Tris-Glycine SDS Running Buffer. For native proteins, we recommend using Novex® Tris-Glycine Native Sample Buffer and Novex® Tris-Glycine Native Running Buffer.

For transferring your proteins to membrane, use Novex® Tris-Glycine Transfer Buffer. Transfers can be done using the Xcell II™ Blot Module or using the iBlot® Gel Transfer Device.

Related Links

•   Use our search tool to find the Novex® Tris-Glycine gel that is right for you.
•   See protein migration ranges on Novex® Tris-Glycine gels.

For Research Use Only. Not for use in diagnostic procedures.
规格
Unit Size10 gels (1 box)
内容与储存
One box contains 10 gels. Store in refrigerator (2–8°C). Do not freeze. Shelf life is 4 weeks.

常见问题解答 (FAQ)

我正在以恒定电压进行Tris-甘氨酸凝胶转印,但电流读数高于预期起始电流。可能因为什么?

电流异常升高的最常见原因是转膜缓冲液。如果转膜缓冲液浓度太高,会导致电导率增加和电流升高。如果不小心用Tris-HCl代替了转膜缓冲液所需的Tris base,也会导致高电流。Tris-HCl可使缓冲液pH降低,引起电导率和电流升高,从而导致过热。我们建议检查转膜缓冲液及其试剂成分,然后重新稀释或重新配制缓冲液。

你们是否有使用Bio-Rad半干转设备对Tris-甘氨酸凝胶进行半干转的实验方案?

以下是经过优化的Bio-Rad半干转设备转印方案。Tris-甘氨酸凝胶转印可使用NuPAGE转膜缓冲液。

1.工作转膜缓冲液:含10%甲醇、1:1,000抗氧化剂的2X NuPAGE转膜缓冲液(Bis-Tris 50 mM和Bicine 50 mM)。如果您需要使用NuPAGE 20X转膜缓冲液(货号NP0006)配制100 mL工作缓冲液,则按下述配方混合:10 mL 20X转膜缓冲液、10 mL甲醇、100 µL抗氧化剂和80 mL去离子水。
2.滤纸:三明治中经转膜缓冲液浸泡的滤纸,是半干转槽中唯一的缓冲液储层。若使用Invitrogen预切膜/滤纸三明治,则凝胶(或膜)两侧至少需要使用3层滤纸(每张滤纸厚0.4 mm)。在组装一个凝胶/膜三明治时,在工作转膜缓冲液(按步骤1配制)中预先浸泡6张Invitrogen滤纸(或2张厚滤纸)和1张膜,然后按以下顺序在阳极板上组装三明治:滤纸--滤纸--滤纸--膜--凝胶--滤纸--滤纸--滤纸。
3.转印条件:我们发现在Bio-Rad半干转仪中使用NuPAGE转膜缓冲液进行转印的最佳条件是电压15 V、转印时间15-30分钟。其他生产商生产的半干转设备,应按照其相应的说明进行使用。
4.转印大分子量蛋白质(≥100 kDa)时,可在组装三明治前,将凝胶置于含0.02-0.04% SDS 的2X NuPAGE转膜缓冲液(无甲醇)中预平衡10分钟。请注意,转印Tris-甘氨酸凝胶时,使用Bio-Rad Trans-Blot SD半干转槽搭配NuPAGE转膜缓冲液的转印效率低于使用XCell II转印模块(半湿转)搭配Tris-甘氨酸转膜缓冲液(货号LC3675)。

我能否使用Invitrogen半干转仪对Tris-甘氨酸凝胶进行半干转?

可以,我们建议使用含10%甲醇的2XTris-甘氨酸转膜缓冲液,在20V恒定电压下转印30-60分钟。

我的凝胶电泳速度比正常速度快,且分辨率较差。可能原因是什么?

以下是可能原因和解决方案:

-使用了浓度过高或错误的缓冲液。应检查缓冲液配方;必要时,稀释或重新配制。
-电压、电流或功率设置过高。将电源条件降低至推荐的电泳条件。

我的凝胶无法电泳。你们能否帮我排除故障?

请务必查看电源、设备或凝胶是否存在问题。通常,切断电源或开盖查看是否有连接错误可帮助解决问题。同时,应检查凝胶盒底部的胶带是否已去除以及缓冲液核心装置是否损坏。此外,应确保电泳槽中的缓冲液足以浸没凝胶的上样孔。

引用和文献 (3)

引用和文献
Abstract
Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity.
Authors:Yao XL, Cowan MJ, Gladwin MT, Lawrence MM, Angus CW, Shelhamer JH,
Journal:J Biol Chem
PubMed ID:10358078
The effect of the glucocorticosteroid, dexamethasone, on arachidonic acid (AA) release and on protein levels of p11 and cytosolic phospholipase A2 (cPLA2) was studied in two epithelial cell lines, HeLa cells and BEAS-2B cells. Dexamethasone treatment of HeLa cells and BEAS-2B cells increased cellular p11 protein and mRNA levels in ... More
Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket.
Authors:Hammond ME, Shyamala V, Siani MA, Gallegos CA, Feucht PH, Abbott J, Lapointe GR, Moghadam M, Khoja H, Zakel J, Tekamp-Olson P,
Journal:J Biol Chem
PubMed ID:8626516
To determine the regions of interleukin-8 (IL-8) that allow high affinity and interleukin-8 receptor type 1 (IL8R1)-specific binding of chemokines, we produced chimeric proteins containing structural domains from IL-8, which binds to both IL8R1 and interleukin-8 receptor type 2 (IL8R2) with high affinity, and from GRO gamma, which does not ... More
The 13-kD FK506 binding protein, FKBP13, interacts with a novel homologue of the erythrocyte membrane cytoskeletal protein 4.1.
Authors:Walensky LD, Gascard P, Fields ME, Blackshaw S, Conboy JG, Mohandas N, Snyder SH,
Journal:J Cell Biol
PubMed ID:9531554
We have identified a novel generally expressed homologue of the erythrocyte membrane cytoskeletal protein 4.1, named 4.1G, based on the interaction of its COOH-terminal domain (CTD) with the immunophilin FKBP13. The 129-amino acid peptide, designated 4.1G-CTD, is the first known physiologic binding target of FKBP13. FKBP13 is a 13-kD protein ... More